Semaglutide
Semaglutide is a GLP-1 receptor agonist active pharmaceutical ingredient. It is also used in separate FDA-approved injectable medications manufactured by Novo Nordisk, which Weight Method does not dispense or prescribe. Our prescribing providers issue patient-specific prescriptions for compounded semaglutide, which is dispensed by U.S.-licensed 503A compounding pharmacies. Weight Method's compounded semaglutide program is $329/month all-inclusive at the standard plan and $154/month on the 12-month commitment, including provider evaluation, ongoing supervision, dosing management, and home shipping. Compounded semaglutide is not FDA-approved.
Compounded Semaglutide prescribed by licensed providers. Delivered to your door.
From 2,000+ patients · Semaglutide is already seeing results
Semaglutide is the active ingredient in an FDA-approved GLP-1 receptor agonist for chronic weight management. Weight Method offers compounded Semaglutide, prescribed by licensed providers, starting at $199/month with direct shipping.
Key Fact
Semaglutide is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. Weight Method's compounded semaglutide program is dispensed by U.S.-licensed 503A compounding pharmacies starting at $154/month. Compounded semaglutide is not FDA-approved.
Source: Weight Method clinical team
How does Semaglutide work for weight loss?
Semaglutide mimics GLP-1 hormones to reduce hunger and slow gastric emptying. Compounded semaglutide is not FDA-approved.
Semaglutide works by mimicking GLP-1, a naturally occurring hormone your body releases after eating that signals fullness to your brain. By activating GLP-1 receptors in the hypothalamus, semaglutide reduces hunger, curbs cravings, and helps you feel satisfied with smaller portions. It also slows gastric emptying, meaning food stays in your stomach longer, which naturally extends the feeling of satiety between meals. Over time, this leads to a sustained caloric deficit without the constant willpower battle associated with traditional dieting.
What is the Semaglutide dosing schedule?
Start at 0.25mg weekly, escalating monthly through 0.5mg, 1mg, 1.7mg, up to 2.4mg maintenance dose over 16-20 weeks.
Treatment follows a gradual dose-escalation protocol designed to minimize side effects and allow your body to adjust. You start at 0.25mg once weekly for the first four weeks, then increase to 0.5mg for weeks five through eight. From there, your provider may increase the dose monthly in increments -- 1mg, 1.7mg, and up to a maximum of 2.4mg -- based on your tolerance and weight loss progress. Most patients reach their maintenance dose within 16 to 20 weeks, and your Weight Method provider monitors your progress at every step to optimize results.
What are the common side effects of Semaglutide?
The most common side effects are nausea, vomiting, diarrhea, and constipation, typically mild and decreasing after the first 4-8 weeks of treatment.
The most common side effects of semaglutide are gastrointestinal and typically occur during the first few weeks or after dose increases. These include nausea, diarrhea, vomiting, constipation, and abdominal discomfort -- most of which are mild to moderate and subside as your body adjusts. The gradual dose-escalation schedule is specifically designed to reduce these effects. Serious side effects are rare but can include pancreatitis, gallbladder issues, and allergic reactions; your Weight Method provider will review your full medical history to ensure semaglutide is safe for you.
Who qualifies for Semaglutide treatment?
Adults with BMI ≥30, or BMI ≥27 with conditions like type 2 diabetes or high blood pressure, aged 18+, who are not pregnant.
You may be eligible for semaglutide if you have a BMI of 30 or greater (classified as obesity) or a BMI of 27 or greater with at least one weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol. Candidates must be 18 years of age or older and should not be pregnant, planning to become pregnant, or breastfeeding. A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) is a contraindication. Take the Weight Method quiz to find out in under two minutes whether semaglutide is right for you.
Your Treatment Options
Compounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.
